RxDoctor Payments Data

Matthew Griffith, OD

Optometry · Meadville, PANPI 1871223982

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 43 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by Tarsus Pharmaceuticals, Inc. at 27.6% of the total. 2025 is the largest year on record at $637, 3.8 times the $169 reported in 2023. Among optometry clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$1,200in general payments, 2019–2025

Across 43 payments — averaging $27.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Tarsus Pharmaceuticals, Inc.$332
  • Biotissue Holdings Inc.$281
  • Mallinckrodt Hospital Products Inc.$146
  • Alcon$131
  • Sun Pharmaceutical Industries Inc.$125
  • Bausch & Lomb Americas Inc.$76
  • plus $110 from 4 others

What the payments were for

  • Food & beverage$1,200100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,200 in reported general payments places this provider in the 95th percentile of 75 optometry providers in Pennsylvania.

See all optometry providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$157,127
Medicare patients
811
Services billed
1,717

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost135$53,601
RestasisCyclosporine20$19,443
Cyclosporine13$11,321
CombiganBrimonidine Tartrate/Timolol40$10,137
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol79$8,734
VyzultaLatanoprostene Bunod22$5,985
Latanoprost318$2,529
Alphagan PBrimonidine Tartrate11$2,103
Travoprost13$1,817
Prednisolone Acetate67$1,561
Brimonidine Tartrate28$1,544
Fluorometholone15$1,065
Loteprednol Etabonate11$861
Timolol Maleate90$646
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat47$588

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan, Alphagan P$25$85,284206 claims
Bausch & Lomb Americas Inc.Vyzulta$76$5,98522 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 75 optometry providers in Pennsylvania.

Other optometry in Meadville

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →